相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection
Kelly E. Dooley et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes
David W. Haas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Dependence of Efavirenz- and Rifampicin-Isoniazid-Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia
Julie Bertrand et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype
Helen M. McIlleron et al.
AIDS (2013)
Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
Anne F. Luetkemeyer et al.
CLINICAL INFECTIOUS DISEASES (2013)
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
Tanuja N. Gengiah et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Emily R. Holzinger et al.
PHARMACOGENETICS AND GENOMICS (2012)
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy
Awewura Kwara et al.
AIDS (2011)
Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers
Yenny et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Salim S. Abdool Karim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Francois-Xavier Blanc et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Diane V. Havlir et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India
Geetha Ramachandran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women
Monica Gandhi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Clinical impact of patient population differences and genomic variation in efavirenz therapy
Jennifer King et al.
AIDS (2008)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
分享论文
